MediGene AG is a publicly listed (Frankfurt: MDG, prime standard) biotechnology company headquartered in Martinsried/Munich, Germany. MediGene is the first German biotech company to
have revenues from marketed products. It has various drug candidates in clinical development and possesses innovative platform technologies. MediGene focuses on clinical research
and development of novel drugs against cancer and autoimmune diseases.
Further Information
For further information please see our press releases, have a look at our annual and quarterly reports, or contact us by phone or
e-mail.
MediGene at a glance
- founded in 1994 as a Munich Gene Center spin-off
- June 2000: IPO, listed on the Frankfurt Stock Exchange
- January 2001: acquisition of the US biotechnology company NeuroVir
- 2004: Acquisition of products and technology of Munich Biotech AG
- 2006: Acquisition of the British biotechnology company Avidex Limited
- about 60 employees
- focus on cancer
- revenues generated from two marketed drugs
- further drug candidates undergoing clinical trials
- novel technology platforms
|
 |
|
|
|
|
MediGene, Inc.
San Diego, CA
How to find MediGene, Inc. |
MediGene, Ltd.
Milton Park, Oxford, GB
|
|
|
|
